Referencias

Artículos clave

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. June 2012 [internet publication].Texto completo external link opens in a new window

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for glomerulonephritis. June 2012 [internet publication].Texto completo external link opens in a new window

Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.Resumen external link opens in a new window

Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020 Feb;43(2):487-93.Texto completo external link opens in a new windowResumen external link opens in a new window

Chang AR, Lóser M, Malhotra R, et al. Blood pressure goals in patients with CKD: a review of evidence and guidelines. Clin J Am Soc Nephrol. 2019 Jan 7;14(1):161-9.Texto completo external link opens in a new windowResumen external link opens in a new window

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1-59.Texto completo external link opens in a new window

Locatelli F, Aljama P, Canaud B, et al; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50.Texto completo external link opens in a new windowResumen external link opens in a new window

Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62.Texto completo external link opens in a new windowResumen external link opens in a new window

Artículos de referencia

1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. June 2012 [internet publication].Texto completo external link opens in a new window

2. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for glomerulonephritis. June 2012 [internet publication].Texto completo external link opens in a new window

3. Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet. 2017 Mar 25;389(10075):1238-52.Resumen external link opens in a new window

4. Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016 Jul 6;11(7):e0158765.Texto completo external link opens in a new windowResumen external link opens in a new window

5. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020 Feb 29;395(10225):709-33.Texto completo external link opens in a new windowResumen external link opens in a new window

6. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-1858.Texto completo external link opens in a new windowResumen external link opens in a new window

7. Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-17.Texto completo external link opens in a new windowResumen external link opens in a new window

8. Myers OB, Pankratz VS, Norris KC, et al. Surveillance of CKD epidemiology in the US - a joint analysis of NHANES and KEEP. Sci Rep. 2018 Oct 26;8(1):15900.Texto completo external link opens in a new windowResumen external link opens in a new window

9. McClellan WM, Satko SG, Gladstone E, et al. Individuals with a family history of ESRD are a high-risk population for CKD: implications for targeted surveillance and intervention activities. Am J Kidney Dis. 2009 Mar;53(3 suppl 3):S100-6.Resumen external link opens in a new window

10. Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442-8.Texto completo external link opens in a new windowResumen external link opens in a new window

11. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-45.Texto completo external link opens in a new windowResumen external link opens in a new window

12. Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2-7.Texto completo external link opens in a new window

13. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs. 2019 Mar;79(4):365-79.Texto completo external link opens in a new windowResumen external link opens in a new window

14. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System, USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. 2006 [internet publication].Texto completo external link opens in a new window

15. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998 Nov 12;339(20):1448-56.Resumen external link opens in a new window

16. Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003 Apr;284(4):F863-9.Texto completo external link opens in a new windowResumen external link opens in a new window

17. Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol. 2000 Apr;278(4):F676-83.Texto completo external link opens in a new windowResumen external link opens in a new window

18. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 Nov;60(5):850-86.Texto completo external link opens in a new windowResumen external link opens in a new window

19. Hommos MS, Glassock RJ, Rule AD. Structural and functional changes in human kidneys with healthy aging. J Am Soc Nephrol. 2017 Oct;28(10):2838-44.Texto completo external link opens in a new windowResumen external link opens in a new window

20. Mallappallil M, Friedman EA, Delano BG, et al. Chronic kidney disease in the elderly: evaluation and management. Clin Pract (Lond). 2014;11(5):525-35.Texto completo external link opens in a new windowResumen external link opens in a new window

21. Calderon-Margalit R, Golan E, Twig G, et al. History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med. 2018 Feb 1;378(5):428-38.Texto completo external link opens in a new windowResumen external link opens in a new window

22. Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006 Aug 1;164(3):263-71.Texto completo external link opens in a new windowResumen external link opens in a new window

23. Chang AR, Grams ME, Ballew SH, et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ. 2019 Jan 10;364:k5301.Texto completo external link opens in a new windowResumen external link opens in a new window

24. Whaley-Connell A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017 Aug;92(2):313-23.Resumen external link opens in a new window

25. Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002 Sep;13(9):2363-70.Texto completo external link opens in a new windowResumen external link opens in a new window

26. Helin HJ, Korpela MM, Mustonen JT, et al. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995 Feb;38(2):242-7.Resumen external link opens in a new window

27. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005 Jan;16(1):180-8.Texto completo external link opens in a new windowResumen external link opens in a new window

28. Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995 Apr;25(4):515-33.Resumen external link opens in a new window

29. Henrich WL, Clark RL, Kelly JP, et al. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the National Analgesic Nephropathy Study. J Am Soc Nephrol. 2006 May;17(5):1472-80.Texto completo external link opens in a new windowResumen external link opens in a new window

30. De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med. 1998 Feb 12;338(7):446-52.Resumen external link opens in a new window

31. Nashar K, Fried LF. Hyperuricemia and the progression of chronic kidney disease: is uric acid a marker or an independent risk factor? Adv Chronic Kidney Dis. 2012 Nov;19(6):386-91.Resumen external link opens in a new window

32. Kumagai T, Ota T, Tamura Y, et al. Time to target uric acid to retard CKD progression. Clin Exp Nephrol. 2017 Apr;21(2):182-92.Resumen external link opens in a new window

33. Jordan DM, Choi HK, Verbanck M, et al. No causal effects of serum urate levels on the risk of chronic kidney disease: A Mendelian randomization study. PLoS Med. 2019 Jan;16(1):e1002725.Texto completo external link opens in a new windowResumen external link opens in a new window

34. Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020 Jun 25;382(26):2504-13.Resumen external link opens in a new window

35. Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020 Jun 25;382(26):2493-503.Resumen external link opens in a new window

36. de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004 Dec;66(6):2109-18.Resumen external link opens in a new window

37. Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007 Sep 27;357(13):1316-25.Resumen external link opens in a new window

38. National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. 2015 [internet publication].Texto completo external link opens in a new windowResumen external link opens in a new window

39. Arnold R, Issar T, Krishnan AV, et al. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis. 2016 Jan-Dec;5:2048004016677687.Texto completo external link opens in a new windowResumen external link opens in a new window

40. Khanna R. Clinical presentation & management of glomerular diseases: hematuria, nephritic & nephrotic syndrome. Mo Med. 2011 Jan-Feb;108(1):33-6.Texto completo external link opens in a new windowResumen external link opens in a new window

41. Levey AS, Gansevoort RT, Coresh J, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US Food and Drug Administration and European Medicines Agency. Am J Kidney Dis. 2020 Jan;75(1):84-104.Texto completo external link opens in a new windowResumen external link opens in a new window

42. Lee J, Nicholl DD, Ahmed SB, et al. The prevalence of restless legs syndrome across the full spectrum of kidney disease. J Clin Sleep Med. 2013 May 15;9(5):455-9.Texto completo external link opens in a new windowResumen external link opens in a new window

43. Matsushita K, Mahmoudi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012 May 9;307(18):1941-51.Texto completo external link opens in a new windowResumen external link opens in a new window

44. National Institute for Health and Care Excellence. Clinical guideline CG182: chronic kidney disease disease in adults: assessment and management. 2015 [internet publication].Texto completo external link opens in a new window

45. Montañés Bermúdez R, Gràcia García S, Pérez Surribas D, et al. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrologia. 2011;31(3):331-45.Texto completo external link opens in a new windowResumen external link opens in a new window

46. Davenport MS, Perazella MA, Yee J, et al. Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology. 2020 Mar;294(3):660-8.Texto completo external link opens in a new windowResumen external link opens in a new window

47. Woolen SA, Shankar PR, Gagnier JJ, et al. Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med. 2019 Dec 9;180(2):223-30.Resumen external link opens in a new window

48. Collins AJ, Gilbertson DT, Snyder JJ, et al. Chronic kidney disease awareness, screening and prevention: rationale for the design of a public education program. Nephrology (Carlton). 2010 Jun;15 Suppl 2:37-42.Resumen external link opens in a new window

49. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 Nov;3(3):259-303.Texto completo external link opens in a new window

50. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92.Texto completo external link opens in a new windowResumen external link opens in a new window

51. Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73.Texto completo external link opens in a new windowResumen external link opens in a new window

52. American Diabetes Association. Standards of medical care in diabetes - 2020. Diabetes Care. Jan 2020 [internet publication].Texto completo external link opens in a new window

53. Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020 Feb;43(2):487-93.Texto completo external link opens in a new windowResumen external link opens in a new window

54. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in Type 2 diabetes mellitus. Circulation. 2019 Apr 23;139(17):2022-31.Texto completo external link opens in a new windowResumen external link opens in a new window

55. Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome eesults of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017 Jul;40(7):821-31.Texto completo external link opens in a new windowResumen external link opens in a new window

56. Kwon S, Kim YC, Park JY, et al. The long-term effects of metformin on patients with Type 2 diabetic kidney disease. Diabetes Care. 2020 May;43(5):948-55.Resumen external link opens in a new window

57. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017 Sep;60(9):1620-29.Texto completo external link opens in a new windowResumen external link opens in a new window

58. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-9.Resumen external link opens in a new window

59. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-54.Resumen external link opens in a new window

60. Alicic RZ, Neumiller JJ, Johnson EJ, et al. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes. 2019 Feb;68(2):248-57.Texto completo external link opens in a new windowResumen external link opens in a new window

61. Heerspink HJL, Kosiborod M, Inzucchi SE, et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018 Jul;94(1):26-39.Resumen external link opens in a new window

62. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306.Resumen external link opens in a new window

63. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-85.Resumen external link opens in a new window

64. Lo C, Toyama T, Wang Y, et al. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018 Sep 24;(9):CD011798.Texto completo external link opens in a new windowResumen external link opens in a new window

65. Mega C, Teixeira-de-Lemos E, Fernandes R, et al. Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes. J Diabetes Res. 2017;2017:5164292.Texto completo external link opens in a new windowResumen external link opens in a new window

66. Bailey CJ, Marx N. Cardiovascular protection in type 2 diabetes: insights from recent outcome trials. Diabetes Obes Metab. 2019 Jan;21(1):3-14.Resumen external link opens in a new window

67. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.Texto completo external link opens in a new windowResumen external link opens in a new window

68. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo external link opens in a new windowResumen external link opens in a new window

69. Chang AR, Lóser M, Malhotra R, et al. Blood pressure goals in patients with CKD: a review of evidence and guidelines. Clin J Am Soc Nephrol. 2019 Jan 7;14(1):161-9.Texto completo external link opens in a new windowResumen external link opens in a new window

70. Ku E, Sarnak MJ, Toto R, et al. Effect of blood pressure control on long-term risk of end-stage renal disease and death among subgroups of patients with chronic kidney disease. J Am Heart Assoc. 2019 Aug 20;8(16):e012749.Texto completo external link opens in a new windowResumen external link opens in a new window

71. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012 Dec;2(5):337-414.Texto completo external link opens in a new window

72. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60.Texto completo external link opens in a new windowResumen external link opens in a new window

73. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.Texto completo external link opens in a new windowResumen external link opens in a new window

74. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31.Texto completo external link opens in a new windowResumen external link opens in a new window

75. Balamuthusamy S, Srinivasam L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008 May;155(5):791-805.Resumen external link opens in a new window

76. Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59.Texto completo external link opens in a new windowResumen external link opens in a new window

77. Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13.Texto completo external link opens in a new windowResumen external link opens in a new window

78. Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2011 Mar;20(2):146-52.Resumen external link opens in a new window

79. Jablonski KL, Chonchol M. Cardiovascular disease: should statin therapy be expanded in patients with CKD? Nat Rev Nephrol. 2012 Jul 3;8(8):440-1.Resumen external link opens in a new window

80. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):263-75.Texto completo external link opens in a new windowResumen external link opens in a new window

81. Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):251-62.Resumen external link opens in a new window

82. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014 May 31;(5):CD007784.Texto completo external link opens in a new windowResumen external link opens in a new window

83. Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289.Texto completo external link opens in a new windowResumen external link opens in a new window

84. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun;65(6):1991-2002.Resumen external link opens in a new window

85. Johns TS, Yee J, Smith-Jules T, et al. Interdisciplinary care clinics in chronic kidney disease. BMC Nephrol. 2015 Oct 12;16:161.Texto completo external link opens in a new windowResumen external link opens in a new window

86. Shukla AM, Hinkamp C, Segal E, et al. What do the US advanced kidney disease patients want? Comprehensive pre-ESRD patient education (CPE) and choice of dialysis modality. PLoS One. 2019 Apr 9;14(4):e0215091.Texto completo external link opens in a new windowResumen external link opens in a new window

87. Easom AM, Shukla AM, Rotaru D, et al. Home run - results of a chronic kidney disease Telemedicine Patient Education Study. Clin Kidney J. 2019 Aug;1-6:sfz096. Texto completo external link opens in a new window

88. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.Resumen external link opens in a new window

89. Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 Nov 16;355(20):2071-84.Resumen external link opens in a new window

90. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32.Resumen external link opens in a new window

91. Skali H, Parving HH, Parfrey PS, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience. Circulation. 2011 Dec 20;124(25):2903-8.Texto completo external link opens in a new windowResumen external link opens in a new window

92. KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012 Aug;2(4):279-335.Texto completo external link opens in a new window

93. Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013 Jan;61(1):44-56.Resumen external link opens in a new window

94. Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul;66(1):69-74.Resumen external link opens in a new window

95. O'Lone EL, Hodson EM, Nistor I, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2019 Feb 21;(2):CD007857.Texto completo external link opens in a new windowResumen external link opens in a new window

96. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1-59.Texto completo external link opens in a new window

97. Coyne DW, Goldberg S, Faber M, et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6.Texto completo external link opens in a new windowResumen external link opens in a new window

98. Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013 Oct 12;382(9900):1268-77.Resumen external link opens in a new window

99. Shukla AM, Easom A, Singh M, et al. Effects of a comprehensive predialysis education program on the home dialysis therapies: a retrospective cohort study. Perit Dial Int. 2017 Sep-Oct;37(5):542-7.Resumen external link opens in a new window

100. Cassidy BP, Harwood L, Getchell LE, et al. Educational support around dialysis modality decision making in patients with chronic kidney disease: qualitative study. Can J Kidney Health Dis. 2018 Oct 8;5:2054358118803323.Texto completo external link opens in a new windowResumen external link opens in a new window

101. Association for Vascular Access, American Society of Diagnostic and Interventional Nephrology. Preservation of peripheral veins in patients with chronic kidney disease. Mar 2011 [internet publication].Texto completo external link opens in a new window

102. Susantitaphong P, Sewaralthahab K, Balk EM, et al. Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol. 2012;35(6):540-7.Resumen external link opens in a new window

103. National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Jan 2007 [internet publication].Texto completo external link opens in a new window

104. Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009 Feb;53(2):197-207.Resumen external link opens in a new window

105. Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167.Resumen external link opens in a new window

106. O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med. 2012 Feb;15(2):228-35.Texto completo external link opens in a new windowResumen external link opens in a new window

107. Blake PG, Bargman JM, Brimble KS, et al; Canadian Society of Nephrology Work Group on Adequacy of Peritoneal Dialysis. Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011. Perit Dial Int. 2011 Mar-Apr;31(2):218-39.Resumen external link opens in a new window

108. Berdud I, Arenas MD, Bernat A, et al; Grupo de Trabajo de Hemodiálisis Extrahospitalaria (Outpatient Haemodialysis Group). Appendix to dialysis centre guidelines: recommendations for the relationship between outpatient haemodialysis centres and reference hospitals. Opinions from the Outpatient Dialysis Group. Grupo de Trabajo de Hemodiálisis Extrahospitalaria. Nefrologia. 2011;31(6):664-9.Texto completo external link opens in a new windowResumen external link opens in a new window

109. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev. 2018 Oct 4;(10):CD001892.Texto completo external link opens in a new windowResumen external link opens in a new window

110. Clase CM, Smyth A. Chronic kidney disease: diet. BMJ Clin Evid. 2015 Jun 29;2015:2004.Texto completo external link opens in a new windowResumen external link opens in a new window

111. Segura J, García-Donaire JA, Ruilope LM. Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol. 2005;16(suppl 1):S64-S66.Texto completo external link opens in a new windowResumen external link opens in a new window

112. Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12.Texto completo external link opens in a new windowResumen external link opens in a new window

113. Liu Z, Su G, Guo X, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev. 2015 Sep 16;(9):CD010350.Texto completo external link opens in a new windowResumen external link opens in a new window

114. Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009 Jul;5(7):375-83.Resumen external link opens in a new window

115. Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015 Dec 3;9:6275-83.Texto completo external link opens in a new windowResumen external link opens in a new window

116. Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018 Jun;42(3):188-95.Texto completo external link opens in a new windowResumen external link opens in a new window

117. Leporini C, Pisano A, Russo E, et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res. 2016 May;107:315-32.Resumen external link opens in a new window

118. Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019 Sep 12;381(11):1001-10.Texto completo external link opens in a new windowResumen external link opens in a new window

119. Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019 Sep 12;381(11):1011-22.Texto completo external link opens in a new windowResumen external link opens in a new window

120. Wesson DE, Mathur V, Tangri N, et al. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial. Lancet. 2019 Apr 6;393(10179):1417-27.Resumen external link opens in a new window

121. Wesson DE, Mathur V, Tangri N, et al. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension. Lancet. 2019 Aug 3;394(10196):396-406.Resumen external link opens in a new window

122. Jing Z, Wei-jie Y, Nan Z, et al. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One. 2012;7(8):e43655.Texto completo external link opens in a new windowResumen external link opens in a new window

123. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.Resumen external link opens in a new window

124. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584-90.Texto completo external link opens in a new windowResumen external link opens in a new window

125. Carrera F, Lok CE, de Francisco A, et al; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010 Dec;25(12):4009-17.Texto completo external link opens in a new windowResumen external link opens in a new window

126. Locatelli F, Aljama P, Canaud B, et al; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50.Texto completo external link opens in a new windowResumen external link opens in a new window

127. Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62.Texto completo external link opens in a new windowResumen external link opens in a new window

128. Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinol. 2012 Apr 1;4(2):118-27.Texto completo external link opens in a new windowResumen external link opens in a new window

129. National Kidney Foundation. KDOQI clinical practice guidelines: nutrition in chronic renal failure. Am J Kidney Dis. 2000 Jun;35(6 Suppl 2):S1-140.Texto completo external link opens in a new windowResumen external link opens in a new window

130. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998 Nov;32(5):853-906.Resumen external link opens in a new window

131. KDOQI Workgroup. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153.Texto completo external link opens in a new windowResumen external link opens in a new window

132. Molitoris BA, Froment DH, Mackenzie TA. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. 1989 Dec;36(6):949-53.Resumen external link opens in a new window

133. Warnock DG. Uremic acidosis. Kidney Int. 1988 Aug;34(2):278-87.Resumen external link opens in a new window

134. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43.Resumen external link opens in a new window

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad